Cell cycle-based therapies move forward.
Targeted therapies directed against cell cycle regulators have been difficult to translate into the clinic. In this issue of Cancer Cell, Choi et al. and Sawai et al. rekindle the therapeutic value of inhibiting specific cyclin-dependent kinase complexes by demonstrating their requirements in the maintenance of breast tumors and leukemias.